Indeed, a PSA level >4 ng/mL and a positive DRE are sufficient ground for patients at risk to undergo prostate biopsy, although the European Randomized Study of Screening for Prostate Cancer (ERSPC) and the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial do not attribute a survival benefit in detecting PCa in case of suspicious DRE (7, 8). The gene discussed is KLK3; the disease is cancer.